Project Grant K99CA312749
Award Date 7/7/26
Completion Date 6/30/28
Dollars Obligated $142K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
- Federal Grant Award Summary Grant Details: Funding Agency: National Cancer Institute (NCI) Federal Grant Program: Cancer Treatment Research (CFDA 93.395) Award Amount: $454,109.00 Award Date: July 3, 2026 Project Period: July 3, 2026 – June 30, 2028 Recipient: Dana-Farber Cancer Institute, Inc. (Boston, MA) Products and Services: Dana-Farber Cancer Institute will develop and test a novel immunotherapy approach that reprograms tumor-associated macrophages (TAMs)—immune cells that typically...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Chicago a Project Grant of $129,285 under the Cancer Research Manpower program (CFDA 93.398) on June 4, 2026, to support research training and workforce development in cancer immunotherapy. The grant funds integrated fatty acid profiling research designed to identify biomarkers and immunomodulatory compounds that enhance the efficacy of anti-tumor immunotherapy, particularly immune checkpoint inhibitors...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $1,098,920 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on August 13, 2025, with a completion date of April 30, 2030. The grant supports fundamental research to understand the transcriptional and epigenetic mechanisms controlling CD8+ tumor-infiltrating lymphocytes (TILs), with specific focus on the transcription...
- Federal Grant Award Summary Beth Israel Deaconess Medical Center, Inc. received a $846,982 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) awarded on August 1, 2025, with an ultimate completion date of July 31, 2032. This seven-year research initiative focuses on understanding the role of innate immunity and epigenetic memory in checkpoint immunotherapy for cancer treatment. The project investigates how the PD-1 (programmed death-1) receptor and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $140,400 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) to develop artificial intelligence (AI)-based methods that integrate genomic and histopathologic data to advance precision cancer medicine. This Project Grant, awarded July 17, 2026, and scheduled for completion by June 30, 2028, funds research focused on creating multimodal, interpretable AI models that combine...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $275,990 to Dana-Farber Cancer Institute, Inc. on September 2, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support development of engineered living materials (ELMs) as programmable therapeutic implants for pancreatic ductal adenocarcinoma (PDAC). The award, scheduled for completion by August 31, 2026, funds research during the K99 phase of an NCI career development fellowship (K00 CA253756). The...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $498,582 Project Grant to Mayo Clinic Jacksonville effective June 1, 2026, through May 31, 2031. This R01 research project grant supports fundamental cancer immunology research focused on identifying and validating acetylation as a post-translational regulatory mechanism for T cell receptor (TCR) signaling. The primary deliverables include mechanistic studies...